• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

整合病毒清除策略——反思现状,展望未来。

Integrated viral clearance strategies-reflecting on the present, projecting to the future.

机构信息

Merck & Co., Inc., Biologics and Vaccines, Downstream Process Development and Engineering Department, Kenilworth, NJ 07033, USA.

出版信息

Curr Opin Biotechnol. 2018 Oct;53:137-143. doi: 10.1016/j.copbio.2018.01.003. Epub 2018 Jan 23.

DOI:10.1016/j.copbio.2018.01.003
PMID:29367164
Abstract

Viral clearance and inactivation are critical steps in ensuring the safety of biological products derived from mammalian cell culture and are a component of an adventitious agent control strategy which spans both upstream and downstream processes. Although these approaches have been sufficient to support the development of biologics to date, the empirical and semi-quantitative nature of the approach leaves some potential gaps. For example, the concept of performing a quantitative risk assessment for the downstream components of virus safety was introduced in ICH Q5A for XMuLV. An ideal future state would be to perform a similar quantitative risk assessment for a range of viruses based on an assessment of potential virus risk in both upstream and downstream processes. This assessment combined with an integrated control strategy (including monitoring) would be extremely beneficial in minimizing potential adventitious agent risks. Significant progress has been achieved towards this goal in the last several years including recent advances in quantification of virus sequences in cell banks (ADVTIG), development of truly modular or generic viral clearance claims for specific unit operations, enhanced controls of upstream media (HTST/nanofiltration) and the use of RVLP for in-process monitoring. The recent shift towards continuous processing has the potential to enhance the criticality of in-line monitoring and the complexity of viral clearance and inactivation (owing to a wide range of potential 'worst case' viral clearance scenarios). However, gaps exist in, firstly, the ability to quantify potential virus risk levels in process streams in real-time, secondly, mechanistic understanding of virus/chromatography media interactions, and thirdly, mechanistic understanding of virus/filter interactions. Some new technologies may also need to be developed to allow for real-time confirmation of virus inactivation and clearance to support process development (both batch and continuous) and assessment of the impact of process deviations during manufacturing. This review paper provides an overview of the current state of an overall integrated control strategy for upstream and downstream processing and highlights the investments that could be pursued to achieve the future state of a quantitative virus risk assessment for a range of viruses. One potential approach to address these gaps is the use of data mining from large, comprehensive and diverse data sets to establish heuristic rules for virus detection, clearance and inactivation followed by specific hypothesis-driven experiments for cases that fall outside of the normal paradigm. Once this approach reaches a mature state suitable for implementation, there is an opportunity to update regulatory guidance (e.g. ICH Q5A) accordingly.

摘要

病毒清除和失活是确保哺乳动物细胞培养衍生的生物制品安全性的关键步骤,也是涵盖上下游工艺的外源因子控制策略的组成部分。尽管这些方法迄今为止足以支持生物技术的发展,但该方法的经验性和半定量性质仍存在一些潜在的差距。例如,在 ICH Q5A 中提出了对病毒安全性的下游组件进行定量风险评估的概念。理想的未来状态是基于对上下游工艺中潜在病毒风险的评估,对一系列病毒进行类似的定量风险评估。这种评估与综合控制策略(包括监测)相结合,将非常有利于最大限度地降低潜在的外源因子风险。在过去几年中,已经在朝着这一目标取得重大进展,包括最近在细胞库中病毒序列的定量方面的进展(ADVTIG)、为特定单元操作开发真正模块化或通用的病毒清除声明、上游介质的增强控制(HTST/纳米过滤)和使用 RVLP 进行过程监测。最近向连续加工的转变有可能增强在线监测的重要性以及病毒清除和失活的复杂性(由于潜在的“最坏情况”病毒清除场景范围广泛)。然而,目前仍然存在一些差距,首先是实时定量过程流中潜在病毒风险水平的能力,其次是病毒/色谱介质相互作用的机制理解,以及病毒/过滤器相互作用的机制理解。可能还需要开发一些新技术,以便实时确认病毒失活和清除,以支持工艺开发(批处理和连续)并评估生产过程中工艺偏差的影响。本文综述了上下游工艺整体综合控制策略的现状,强调了为实现对一系列病毒进行定量病毒风险评估的未来状态而可以进行的投资。解决这些差距的一种潜在方法是使用来自大型、综合和多样化数据集的数据挖掘来建立病毒检测、清除和失活的启发式规则,然后针对超出正常范例的情况进行具体的假设驱动实验。一旦这种方法达到适合实施的成熟状态,就有机会相应地更新监管指南(例如 ICH Q5A)。

相似文献

1
Integrated viral clearance strategies-reflecting on the present, projecting to the future.整合病毒清除策略——反思现状,展望未来。
Curr Opin Biotechnol. 2018 Oct;53:137-143. doi: 10.1016/j.copbio.2018.01.003. Epub 2018 Jan 23.
2
Adapting viral safety assurance strategies to continuous processing of biological products.调整病毒安全性保证策略以适应生物制品的连续生产
Biotechnol Bioeng. 2017 Jan;114(1):21-32. doi: 10.1002/bit.26060. Epub 2016 Aug 17.
3
Limits in virus filtration capability? Impact of virus quality and spike level on virus removal with xenotropic murine leukemia virus.病毒过滤能力的限制?病毒质量和加标水平对异嗜性小鼠白血病病毒去除的影响。
Biotechnol Prog. 2015 Jan-Feb;31(1):135-44. doi: 10.1002/btpr.2020. Epub 2014 Nov 29.
4
Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.2017年病毒清除研讨会会议记录 第5场:设施风险缓解
PDA J Pharm Sci Technol. 2018 Sep-Oct;72(5):511-515. doi: 10.5731/pdajpst.2018.009175. Epub 2018 Jul 20.
5
Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.生物制药行业保障病毒安全性的设施隔离方法:生物制造中偶发因子污染联盟的一项工作。
PDA J Pharm Sci Technol. 2019 Mar-Apr;73(2):191-203. doi: 10.5731/pdajpst.2018.008862. Epub 2018 Oct 25.
6
Suitability of a generic virus safety evaluation for monoclonal antibody investigational new drug applications.通用病毒安全性评估用于单克隆抗体新药申请的适宜性。
Biotechnol Prog. 2019 Sep;35(5):e2850. doi: 10.1002/btpr.2850. Epub 2019 Jun 9.
7
Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations-Purification Unit Operations.2017年病毒清除研讨会会议记录,第2.2场会议:下游加工单元操作-纯化单元操作
PDA J Pharm Sci Technol. 2018 Sep-Oct;72(5):479-487. doi: 10.5731/pdajpst.2018.009126. Epub 2018 Jul 20.
8
The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.贝叶斯分层逻辑回归在模块化病毒灭活声明制定中的应用。
PDA J Pharm Sci Technol. 2019 Nov-Dec;73(6):552-561. doi: 10.5731/pdajpst.2019.010116. Epub 2019 May 17.
9
Proceedings of the 2019 Viral Clearance Symposium, Session 1: Viral Clearance Strategies and Case Studies.2019 年病毒清除研讨会会议记录,第 1 节:病毒清除策略和案例研究。
PDA J Pharm Sci Technol. 2022 Jul-Aug;76(4):297-305. doi: 10.5731/pdajpst.2021.012677. Epub 2021 Dec 15.
10
Evolution of approaches to viral safety issues for biological products.生物制品病毒安全性问题处理方法的演变。
PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):547-56. doi: 10.5731/pdajpst.2011.00818.

引用本文的文献

1
Quantitative Risk Evaluation of Adventitious Agents in Heparin.肝素中杂质的定量风险评估
TH Open. 2023 May 21;7(2):e128-e132. doi: 10.1055/s-0043-1768946. eCollection 2023 Apr.
2
Recombinant mucin biotechnology and engineering.重组黏蛋白生物技术与工程。
Adv Drug Deliv Rev. 2023 Feb;193:114618. doi: 10.1016/j.addr.2022.114618. Epub 2022 Nov 11.
3
Establishment of a keratinocyte and fibroblast bank for clinical applications in Japan.日本用于临床应用的角质形成细胞和成纤维细胞库的建立。
J Artif Organs. 2023 Mar;26(1):45-52. doi: 10.1007/s10047-022-01331-6. Epub 2022 May 5.
4
Nanofiltration of growth media supplemented with human platelet lysates for pathogen-safe xeno-free expansion of mesenchymal stromal cells.用人血小板裂解液补充的生长培养基的纳滤法,用于间充质基质细胞的无病原体、无动物源的扩增。
Cytotherapy. 2020 Aug;22(8):458-472. doi: 10.1016/j.jcyt.2020.04.099. Epub 2020 May 8.
5
Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance.用于病毒纯化和病毒清除的多糖基色谱吸附剂。
J Pharm Anal. 2020 Aug;10(4):291-312. doi: 10.1016/j.jpha.2020.01.002. Epub 2020 Jan 13.
6
Extracellular Vesicles As Nanomedicine: Hopes And Hurdles In Clinical Translation.细胞外囊泡作为纳米医学:临床转化的希望与挑战。
Int J Nanomedicine. 2019 Nov 12;14:8847-8859. doi: 10.2147/IJN.S225453. eCollection 2019.